ÂÜÀòÂÒÂ×

After completing a Master’s degree in cell and molecular biology, Riikka joined the Cancer Gene Therapy Group at the University of Helsinki in 2014 and earned her PhD degree in 2018. During her academic career, she has become a highly skilled expert in oncolytic viruses and cancer immunotherapy. Riikka had a key role in development of TILT´s leading candidate, TILT-123, which is also the main focus of her PhD thesis. Since 2017, Riikka has been part of TILT team and now heads CMC activities and translating the preclinical research into clinical development.